CL2022003738A1 - Uso de antagonistas de coenzima para la ralentización del metabolismo - Google Patents

Uso de antagonistas de coenzima para la ralentización del metabolismo

Info

Publication number
CL2022003738A1
CL2022003738A1 CL2022003738A CL2022003738A CL2022003738A1 CL 2022003738 A1 CL2022003738 A1 CL 2022003738A1 CL 2022003738 A CL2022003738 A CL 2022003738A CL 2022003738 A CL2022003738 A CL 2022003738A CL 2022003738 A1 CL2022003738 A1 CL 2022003738A1
Authority
CL
Chile
Prior art keywords
cells
coenzyme
order
antagonists
slow down
Prior art date
Application number
CL2022003738A
Other languages
English (en)
Inventor
F Coy Johannes
SCHIERL Ralf
Original Assignee
TAVARGENIX GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAVARGENIX GmbH filed Critical TAVARGENIX GmbH
Publication of CL2022003738A1 publication Critical patent/CL2022003738A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of at least one inhibitory structural analog or inhibitory functional analog of a coenzyme (such as thiamine for example) of an enzyme group, the enzyme members of which catalyze anabolic and/or catabolic and/or energy-releasing metabolic reactions that are of essential significance for the functionality of the overall metabolism of cells, in particular mammalian cells. The invention is used to treat patients in order to produce a general successive (in particular also continuous) slowing down of the metabolic processes of endogenous cells and exogenous cells in the body of the patient and thus achieve a slowing down of disease-causing processes in particular
CL2022003738A 2020-06-27 2022-12-23 Uso de antagonistas de coenzima para la ralentización del metabolismo CL2022003738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102020116980.9A DE102020116980A1 (de) 2020-06-27 2020-06-27 Verwendung von Co-Enzym-Antagonisten zur Stoffwechselverlangsamung

Publications (1)

Publication Number Publication Date
CL2022003738A1 true CL2022003738A1 (es) 2023-05-05

Family

ID=76844958

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003738A CL2022003738A1 (es) 2020-06-27 2022-12-23 Uso de antagonistas de coenzima para la ralentización del metabolismo

Country Status (8)

Country Link
US (1) US20230226060A1 (es)
EP (1) EP4135701A1 (es)
JP (1) JP2023530750A (es)
CN (1) CN115989037A (es)
CA (1) CA3177633A1 (es)
CL (1) CL2022003738A1 (es)
DE (1) DE102020116980A1 (es)
WO (1) WO2021259423A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102021109341A1 (de) 2021-04-14 2022-10-20 TAVARGENIX GmbH TKTL1 Inhibitoren für die antivirale Therapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20090209554A1 (en) * 2004-03-24 2009-08-20 Array Biopharma Inc. Thiazoliums as transketolase inhibitors
US20060002922A1 (en) * 2004-06-30 2006-01-05 Minkon Biotechnology, Inc. Method for preventing or treating obesity by modulating the activities of the pentose phosphate patway
DK2256500T3 (da) * 2005-03-07 2014-07-14 Dr Johannes F Coy Anvendelse af inhibitorer af enzymet TKTL1
US11813277B2 (en) * 2018-06-27 2023-11-14 The Regents Of The University Of California Methods and agents for modulating inflammation

Also Published As

Publication number Publication date
JP2023530750A (ja) 2023-07-19
CA3177633A1 (en) 2021-12-30
WO2021259423A1 (de) 2021-12-30
US20230226060A1 (en) 2023-07-20
CN115989037A (zh) 2023-04-18
DE102020116980A1 (de) 2021-12-30
EP4135701A1 (de) 2023-02-22

Similar Documents

Publication Publication Date Title
Gerbin et al. The winding road to regenerating the human heart
CL2022003738A1 (es) Uso de antagonistas de coenzima para la ralentización del metabolismo
Tsutsui et al. Effect of tetrahydrobiopterin on endothelial function in canine middle cerebral arteries
IN2015DN01616A (es)
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
MX2019006288A (es) Metodos y composiciones para el uso de celulas t terapeuticas en combinacion con inhibidores de quinasa.
Hong et al. Stem cell aging in the skeletal muscle: The importance of communication
MX2023003296A (es) Generacion de lineas de cardiomiocitos auriculares y ventriculares a partir de celulas madre pluripotentes humanas.
De Rasmo et al. The β-adrenoceptor agonist isoproterenol promotes the activity of respiratory chain complex I and lowers cellular reactive oxygen species in fibroblasts and heart myoblasts
RU2018131519A (ru) Стромальные стволовые клетки жировой ткани для использования в лечении рефракторных сложных перианальных фистул при болезни крона
Xu et al. Phosphatidylserine enhances osteogenic differentiation in human mesenchymal stem cells via ERK signal pathways
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
GB201202561D0 (en) Treatment of skin disorders
Zhang et al. Cyclic tensile stress promotes osteogenic differentiation of adipose stem cells via ERK and p38 pathways
BR112022000066A2 (pt) Método para determinar um tempo de início e/ou uma excitabilidade de uma região do cérebro que não é observada como recrutada ou não observada como não recrutada em uma atividade convulsiva de um cérebro de paciente epiléptico
Peacock et al. Administration of beta-aminopropionitrile to human beings with urethral strictures: A prelimary report.
DE602004022145D1 (de) Von monozyten stammende multipotente zelle momc
ES2196027T3 (es) Tratamiento de enfermedades vasculares degenerativas mediante modulacion de la produccion o actividad del oxido nitrico exogeno.
KR20170099382A (ko) 줄기세포의 효능 개선을 위한 조성물 및 방법
WO2014072720A3 (en) Cell differentiation
BR112017023660A2 (pt) ensaio de potência
BR112014028716A2 (pt) endoglicanases melhoradas para tratamento de material celulósico
BR112023019951A2 (pt) Linhagens hematopoiéticas derivadas de células-tronco pluripotentes
MX2023005491A (es) Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas.
Hittelman et al. Cyclic AMP and the mechanism of action of the prostaglandins